ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2185

Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2

Brendan M. Giles1 and Susan A. Boackle2, 1University of Colorado School of Medicine, Aurora, CO, 2Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: B cells, complement and polymorphism, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors

Session Type: Abstract Submissions (ACR)

Background/Purpose: We have recently identified a variant in intron 1 of complement receptor 2 (CR2/CD21) that is associated with decreased risk of lupus (rs1876453; Pmeta=4.2×10-4, OR=0.85). Its effect was strongest in subjects with anti-dsDNA antibodies (Pmeta=7.6×10-7, OR=0.71), suggesting a preferential association with this B cell-driven endophenotype. Peripheral blood B cells from healthy subjects with the rs1876453 minor allele had increased levels of complement receptor 1 (CR1/CD35) resulting in an altered CR1:CR2 ratio on the cell surface. CR1 binds the C3b and iC3b fragments of C3 and is a required cofactor for the degradation of C3b to the CR2-specific ligand C3dg. While crosslinking of CR2 and the B cell antigen receptor is known to lower the activation threshold, the role of CR1 during complement-dependent B cell activation remains unclear. We hypothesize that increased CR1 levels associated with the protective allele facilitate complement processing and modify B cell activation.

Methods: A novel CR1 ligand (biot-C3b) was developed by biotinylating C3b in the thioester domain, the site of antigen attachment. The biotin orientation enables multimers of biot-C3b to be formed that mimic the natural C3b-coated immune complexes that are targets for CR1-mediated processing. Multimeric and monomeric CR1 ligands were generated by incubating biot-C3b with and without streptavidin, respectively. For analysis of CR1-mediated processing, ligand binding was evaluated by flow cytometry using primary B cells and cofactor activity was determined by incubating CR1 (soluble or cell bound) with biot-C3b and factor I followed by SDS-PAGE.

Results: Multimers of biot-C3b were processed by CR1 more efficiently than monomers as demonstrated by increased B cell binding and more complete degradation to C3dg. In solution, higher CR1 concentrations resulted in more rapid conversion of biot-C3b to its degradation products. On primary B cells, elevated levels of CR1 associated with the protective allele enhanced biot-C3b processing with increased binding capacity (p<0.05) and hastened degradation kinetics.

Conclusion: Here, we show that increases in CR1 levels, both in solution and on primary cells, enhance the processing of biot-C3b multimers. These data suggest that the elevated B cell CR1 levels associated with the protective minor allele at rs1876453 will result in increased generation of C3dg-coated complexes that bind CR2. Further characterization of the downstream effects of these augmented signals through CR1 and CR2 are likely to provide mechanistic insights into the protective effect of rs1876453 as well as enhance the understanding of how the complement system modulates B cell activation.


Disclosure:

B. M. Giles,
None;

S. A. Boackle,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alterations-in-b-cell-complement-processing-related-to-a-lupus-associated-variant-in-complement-receptor-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology